In the latest session, AbbVie Inc. (NYSE: ABBV) closed at $159.79 up 1.71% from its previous closing price of $157.11. In other words, the price has increased by $+2.68 from its previous closing price. On the day, 5350192 shares were traded. ABBV stock price reached its highest trading level at $159.88 during the session, while it also had its lowest trading level at $157.56.
For a deeper understanding of AbbVie Inc.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 23.36 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 22.99. For the most recent quarter (mrq), Quick Ratio is recorded 0.80 and its Current Ratio is at 0.90. In the meantime, Its Debt-to-Equity ratio is 4.35 whereas as Long-Term Debt/Eq ratio is at 3.78.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Credit Suisse on November 18, 2022, initiated with a Outperform rating and assigned the stock a target price of $170.
Atlantic Equities Downgraded its Overweight to Neutral on August 01, 2022, whereas the target price for the stock was revised from $178 to $162.
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 23 when SEVERINO MICHAEL sold 79,801 shares for $150.90 per share. The transaction valued at 12,041,780 led to the insider holds 152,103 shares of the business.
SEVERINO MICHAEL sold 100,000 shares of ABBV for $15,404,400 on May 17. The Vice Chairman now owns 152,103 shares after completing the transaction at $154.04 per share. On May 16, another insider, Gosebruch Henry O, who serves as the EVP, Chief Strategy Officer of the company, sold 83,960 shares for $155.00 each. As a result, the insider received 13,013,800 and left with 16,623 shares of the company.
As of this moment, AbbVie’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.29, and their Forward P/E ratio for the next fiscal year is 13.91. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.80 while its Price-to-Book (P/B) ratio in mrq is 17.70.
Stock Price History:
Over the past 52 weeks, ABBV has reached a high of $175.91, while it has fallen to a 52-week low of $115.01. The 50-Day Moving Average of the stock is 145.15, while the 200-Day Moving Average is calculated to be 148.40.
For the past three months, ABBV has traded an average of 5.50M shares per day and 5.92M over the past ten days. A total of 1.77B shares are outstanding, with a floating share count of 1.77B. Insiders hold about 0.11% of the company’s shares, while institutions hold 70.90% stake in the company. Shares short for ABBV as of Oct 13, 2022 were 14M with a Short Ratio of 13.80M, compared to 12.95M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 0.79% and a Short% of Float of 0.79%.
Dividends & Splits
According to the company, the forward annual dividend rate for ABBV is 5.92, from 3.66 in the trailing year. Against a Trailing Annual Dividend Yield of 2.33%, it implies a Forward Annual Dividend Yield of 3.67%. The stock’s 5-year Average Dividend Yield is 4.31.
There are 15 different market analysts currently analyzing its stock. On average, analysts expect EPS of $3.57 for the current quarter, with a high estimate of $3.7 and a low estimate of $3.51, while EPS last year was $2.83. The consensus estimate for the next quarter is $3.75, with high estimates of $3.86 and low estimates of $3.55.
Analysts are recommending an EPS of between $13.99 and $13.71 for the fiscal current year, implying an average EPS of $13.86. EPS for the following year is $11.84, with 22 analysts recommending between $13.41 and $10.88.
A total of 22 analysts have provided revenue estimates for ABBV’s current fiscal year. The highest revenue estimate was $59.54B, while the lowest revenue estimate was $58.6B, resulting in an average revenue estimate of $58.92B. In the same quarter a year ago, actual revenue was $56.12B, up 5.00% from the average estimate. Based on 22 analysts’ estimates, the company’s revenue will be $54.96B in the next fiscal year. The high estimate is $58.54B and the low estimate is $52.25B. The average revenue growth estimate for next year is down -6.70% from the average revenue estimate for this year.